CA2198361A1 - Intracellular delivery of chemical agents to a specific cell type - Google Patents

Intracellular delivery of chemical agents to a specific cell type

Info

Publication number
CA2198361A1
CA2198361A1 CA002198361A CA2198361A CA2198361A1 CA 2198361 A1 CA2198361 A1 CA 2198361A1 CA 002198361 A CA002198361 A CA 002198361A CA 2198361 A CA2198361 A CA 2198361A CA 2198361 A1 CA2198361 A1 CA 2198361A1
Authority
CA
Canada
Prior art keywords
chemical agent
seq
receptor
composition
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002198361A
Other languages
English (en)
French (fr)
Inventor
Ramesh K. Prakash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actavis Laboratories UT Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2198361A1 publication Critical patent/CA2198361A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002198361A 1994-09-13 1995-09-12 Intracellular delivery of chemical agents to a specific cell type Abandoned CA2198361A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30577094A 1994-09-13 1994-09-13
US08/305,770 1994-09-13

Publications (1)

Publication Number Publication Date
CA2198361A1 true CA2198361A1 (en) 1996-03-21

Family

ID=23182273

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002198361A Abandoned CA2198361A1 (en) 1994-09-13 1995-09-12 Intracellular delivery of chemical agents to a specific cell type

Country Status (13)

Country Link
EP (1) EP0781139A1 (ja)
JP (1) JPH10505835A (ja)
KR (1) KR970705404A (ja)
CN (1) CN1157570A (ja)
AU (1) AU697469B2 (ja)
BR (1) BR9508951A (ja)
CA (1) CA2198361A1 (ja)
CZ (1) CZ74797A3 (ja)
HU (1) HUT77263A (ja)
MX (1) MX9701860A (ja)
PL (1) PL319100A1 (ja)
WO (1) WO1996008263A1 (ja)
ZA (1) ZA957688B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
WO1999007324A2 (en) * 1997-08-05 1999-02-18 Watson Pharmaceuticals, Inc. Conjugates targeted to the interleukin-2 receptor
CN1616665B (zh) * 1997-11-19 2010-10-06 乔治敦大学 定向脂质体基因送递
DE19926154A1 (de) * 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
US11007272B1 (en) 2016-10-07 2021-05-18 Navidea Biopharmaceuticals, Inc. Compounds and methods for diagnosis and treatment of viral infections
US12006339B2 (en) 2022-05-20 2024-06-11 Navidea Biopharmaceuticals, Inc. CD206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5331090A (en) * 1989-09-08 1994-07-19 California Institute Of Biological Research CR2 ligand compositions and methods for modulating immune cell functions
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease

Also Published As

Publication number Publication date
CN1157570A (zh) 1997-08-20
HUT77263A (hu) 1998-03-02
KR970705404A (ko) 1997-10-09
JPH10505835A (ja) 1998-06-09
AU3550795A (en) 1996-03-29
PL319100A1 (en) 1997-07-21
CZ74797A3 (en) 1997-08-13
EP0781139A1 (en) 1997-07-02
BR9508951A (pt) 1999-04-06
MX9701860A (es) 1997-06-28
AU697469B2 (en) 1998-10-08
ZA957688B (en) 1996-05-13
WO1996008263A1 (en) 1996-03-21

Similar Documents

Publication Publication Date Title
JP2702285B2 (ja) Ｔａｔ由来の輸送ポリペプチド
Jing et al. Role of the human transferrin receptor cytoplasmic domain in endocytosis: localization of a specific signal sequence for internalization.
US5252713A (en) Polymeric carriers for non-covalent drug conjugation
Leifert et al. “Translocatory proteins” and “protein transduction domains”: a critical analysis of their biological effects and the underlying mechanisms
AU695196B2 (en) Nucleic acid transfer system
JP2002514892A (ja) 遺伝子治療における合成ウイルス様粒子の使用
US20040110928A1 (en) Peptide conjugates for drug delivery
AU1193999A (en) J-chain and analogues as epithelial cell targeting conjugates
EP1290153A2 (en) Molecular delivery vehicle for delivery of selected compounds to targets
CA2221269A1 (en) Compositions containing nucleic acids and ligands for therapeutic treatment
EP0975762A1 (en) Type-1 ribosome-inactivating protein
CA2198361A1 (en) Intracellular delivery of chemical agents to a specific cell type
KR20040083429A (ko) 생체분자 전달 모티브 Mph-1-BTM 및 이것의 이용 방법
CA2276046A1 (en) Novel epithelial tissue targeting agent
US20030044961A1 (en) Compositions for transferring active compounds in a cell-specific manner
MXPA97001860A (en) Intracellular supply of chemical agents, to a specific unit of cel
US6770631B1 (en) Non-identical genes and their application in improved molecular adjuvants
CA2165413A1 (en) Methods for peptide synthesis and purification
US5912322A (en) Modified pseudomonas exotoxin PE40
JPH03504729A (ja) マルトースに対して親和性のある物質（ＭａｌＥ）と、ＨＩＶウイルスに対する中和特性を有するＣＤ４タンパク質フラグメントとの融合によって生じた融合ＣＤ４ポリペプチド
EP1007549A1 (en) Compositions and methods for highly efficient transfection
CA2083487A1 (en) Chimeric toxins with improved inter-domain geometry
CA2359650C (en) Pharmaceutical preparations and methods for inhibiting tumors
AU653365C (en) Protein structure of the plant toxin gelonin
WO2005049824A1 (ja) 生体構造認識部位を提示する中空ナノ粒子およびその生産方法、並びにその利用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued